The technology uses multi-level, multi-parameter, diagnostic algorithms to analyse simple, standard blood tests for identifying cancer with better accuracy, compared to traditional screening techniques.
Research validation data from more than 60,000 cases that were independently confirmed by various hospitals and cancer researchers showed that Anpac Bio’s CDA test demonstrated a sensitivity and specificity rate of 75%-90%.
According to the firm, the test does not have any side-effects, generates fewer false-positives, costs less than standard testing, and delivers results within minutes of submitting the sample.
The results from more than 4,000 CDA liquid biopsy tests performed since 2014 by Second Military Medical University and Changhai Hospital (CH) in China, showed that the technology accurately supports early diagnosis and monitors treatment effectiveness, prognosis, and recurrence.
CH Oncology department deputy chief physician Dr Jun-Jie Wu said: “Our preliminarily results indicate that CDA technology has better sensitivity and specificity for early diagnosis, as well as potentially a good tool for treatment assessment for lung cancer and oesophageal cancer than traditional tumour markers.
“It can also play a good role in complementing chest CT (computerised axial tomography) screening for pulmonary nodules.”
Since 2016, Anpac Bio’s CDA technology has been investigated in two clinical studies at the Oncology Department of Shanghai Changzheng Hospital (SCH).
The hospital’s deputy professor Dr Yuan Sheng Zang said that initial findings from these studies indicated better sensitivity and specificity for early-stage screening of cancer compared to other tumour markers.